Thrombolysis with saruplase versus streptokinase in acute myocardial infarction: five-year results of the PRIMI trial
BACKGROUND: Short-term safety and efficacy of thrombolysis with saruplase in acute myocardial infarction have been shown in several trials. To assess long-term outcome of patients treated with saruplase or streptokinase for myocardial infarction, a 5-year follow-up of patients included in the Pro-Ur...
Gespeichert in:
| Hauptverfasser: | , , , , , , , , , , , , , , |
|---|---|
| Dokumenttyp: | Article (Journal) |
| Sprache: | Englisch |
| Veröffentlicht: |
1999
|
| In: |
American heart journal
Year: 1999, Jahrgang: 138, Heft: 3, Pages: 518-524 |
| ISSN: | 1097-6744 |
| DOI: | 10.1016/s0002-8703(99)70155-9 |
| Online-Zugang: | Verlag, lizenzpflichtig, Volltext: https://doi.org/10.1016/s0002-8703(99)70155-9 Verlag, lizenzpflichtig, Volltext: https://www.sciencedirect.com/science/article/abs/pii/S0002870399701559#! 
|
| Verfasserangaben: | M. Spiecker, J. Windeler, F. Vermeer, R. Michels, R. Seabra-Gomes, J. vom Dahl, S. Kerber, F.W. Verheugt, P.W. Westerhof, F.W. Bär, U. Nixdorff, H. Barth, G.R. Hopkins, M.J. von Fisenne, J. Meyer |
MARC
| LEADER | 00000caa a22000002c 4500 | ||
|---|---|---|---|
| 001 | 1755917317 | ||
| 003 | DE-627 | ||
| 005 | 20220819181141.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 210426s1999 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1016/s0002-8703(99)70155-9 |2 doi | |
| 035 | |a (DE-627)1755917317 | ||
| 035 | |a (DE-599)KXP1755917317 | ||
| 035 | |a (OCoLC)1341406046 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rda | ||
| 041 | |a eng | ||
| 084 | |a 33 |2 sdnb | ||
| 100 | 1 | |a Spiecker, Martin |e VerfasserIn |0 (DE-588)1035556308 |0 (DE-627)748730362 |0 (DE-576)383292638 |4 aut | |
| 245 | 1 | 0 | |a Thrombolysis with saruplase versus streptokinase in acute myocardial infarction |b five-year results of the PRIMI trial |c M. Spiecker, J. Windeler, F. Vermeer, R. Michels, R. Seabra-Gomes, J. vom Dahl, S. Kerber, F.W. Verheugt, P.W. Westerhof, F.W. Bär, U. Nixdorff, H. Barth, G.R. Hopkins, M.J. von Fisenne, J. Meyer |
| 264 | 1 | |c 1999 | |
| 300 | |a 7 | ||
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a Computermedien |b c |2 rdamedia | ||
| 338 | |a Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Elektronische Reproduktion der Druck-Ausgabe | ||
| 500 | |a Gesehen am 26.04.2021 | ||
| 520 | |a BACKGROUND: Short-term safety and efficacy of thrombolysis with saruplase in acute myocardial infarction have been shown in several trials. To assess long-term outcome of patients treated with saruplase or streptokinase for myocardial infarction, a 5-year follow-up of patients included in the Pro-Urokinase in Myocardial Infarction Trial was performed. METHODS AND RESULTS: Follow-up data are available from 8 centers on 255 (92.4%) of 276 included patients. The 5-year mortality rate was comparable with 20.8% of patients in the saruplase group and 16.9% in the streptokinase group (odds ratio 1.29, 95% confidence interval 0.69 to 2.42). In both groups, a considerable number of fatal cardiovascular events occurred more than 1 year after study inclusion. Rates of percutaneous transluminal coronary angioplasty and coronary artery bypass grafting were comparable in both groups. Reinfarction within 5 years occurred in 19.0% of patients in the saruplase group and tended to be less frequent at 10.8% after streptokinase treatment (odds ratio 1.94, 95% confidence interval 0.98 to 3.84). In both groups, the majority of reinfarctions took place more than 3 months after study inclusion. The 5-year stroke rate was 3.6% and 7.2% in the saruplase and streptokinase groups, respectively (odds ratio 0.49, 95% confidence interval 0.16 to 1.47). Subjective symptoms of heart failure and angina pectoris were comparable in both groups. CONCLUSIONS: Our data are consistent with a similar long-term outcome for patients treated with saruplase or streptokinase. Despite the low-risk profile of the patient cohort, there were considerable adverse event rates over a 5-year period. | ||
| 650 | 4 | |a Aged | |
| 650 | 4 | |a Angioplasty, Balloon, Coronary | |
| 650 | 4 | |a Cerebrovascular Disorders | |
| 650 | 4 | |a Cohort Studies | |
| 650 | 4 | |a Coronary Artery Bypass | |
| 650 | 4 | |a Female | |
| 650 | 4 | |a Fibrinolytic Agents | |
| 650 | 4 | |a Follow-Up Studies | |
| 650 | 4 | |a Humans | |
| 650 | 4 | |a Male | |
| 650 | 4 | |a Middle Aged | |
| 650 | 4 | |a Myocardial Infarction | |
| 650 | 4 | |a Recombinant Proteins | |
| 650 | 4 | |a Recurrence | |
| 650 | 4 | |a Streptokinase | |
| 650 | 4 | |a Survival Analysis | |
| 650 | 4 | |a Thrombolytic Therapy | |
| 650 | 4 | |a Urokinase-Type Plasminogen Activator | |
| 700 | 1 | |a Windeler, Jürgen |d 1957- |e VerfasserIn |0 (DE-588)172465389 |0 (DE-627)697404188 |0 (DE-576)133327035 |4 aut | |
| 700 | 1 | |a Vermeer, F. |e VerfasserIn |4 aut | |
| 700 | 1 | |a Michels, R. |e VerfasserIn |4 aut | |
| 700 | 1 | |a Seabra-Gomes, R. |e VerfasserIn |4 aut | |
| 700 | 1 | |a vom Dahl, J. |e VerfasserIn |4 aut | |
| 700 | 1 | |a Kerber, S. |e VerfasserIn |4 aut | |
| 700 | 1 | |a Verheugt, F. W. |e VerfasserIn |4 aut | |
| 700 | 1 | |a Westerhof, P. W. |e VerfasserIn |4 aut | |
| 700 | 1 | |a Bär, F. W. |e VerfasserIn |4 aut | |
| 700 | 1 | |a Nixdorff, U. |e VerfasserIn |4 aut | |
| 700 | 1 | |a Barth, H. |e VerfasserIn |4 aut | |
| 700 | 1 | |a Hopkins, G. R. |e VerfasserIn |4 aut | |
| 700 | 1 | |a von Fisenne, M. J. |e VerfasserIn |4 aut | |
| 700 | 1 | |a Meyer, J. |e VerfasserIn |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t American heart journal |d Amsterdam [u.a.] : Elsevier, 1925 |g 138(1999), 3, Seite 518-524 |h Online-Ressource |w (DE-627)313061718 |w (DE-600)2003210-9 |w (DE-576)090883500 |x 1097-6744 |7 nnas |a Thrombolysis with saruplase versus streptokinase in acute myocardial infarction five-year results of the PRIMI trial |
| 773 | 1 | 8 | |g volume:138 |g year:1999 |g number:3 |g pages:518-524 |g extent:7 |a Thrombolysis with saruplase versus streptokinase in acute myocardial infarction five-year results of the PRIMI trial |
| 856 | 4 | 0 | |u https://doi.org/10.1016/s0002-8703(99)70155-9 |x Verlag |x Resolving-System |z lizenzpflichtig |3 Volltext |
| 856 | 4 | 0 | |u https://www.sciencedirect.com/science/article/abs/pii/S0002870399701559#! |x Verlag |z lizenzpflichtig |3 Volltext |
| 951 | |a AR | ||
| 992 | |a 20210426 | ||
| 993 | |a Article | ||
| 994 | |a 1999 | ||
| 998 | |g 172465389 |a Windeler, Jürgen |m 172465389:Windeler, Jürgen |d 910000 |d 999701 |e 910000PW172465389 |e 999701PW172465389 |k 0/910000/ |k 1/910000/999701/ |p 2 | ||
| 999 | |a KXP-PPN1755917317 |e 3917696142 | ||
| BIB | |a Y | ||
| SER | |a journal | ||
| JSO | |a {"relHost":[{"language":["eng"],"recId":"313061718","disp":"Thrombolysis with saruplase versus streptokinase in acute myocardial infarction five-year results of the PRIMI trialAmerican heart journal","note":["Gesehen am 21.09.2020"],"type":{"media":"Online-Ressource","bibl":"periodical"},"titleAlt":[{"title":"AHJ"}],"part":{"extent":"7","volume":"138","text":"138(1999), 3, Seite 518-524","pages":"518-524","issue":"3","year":"1999"},"pubHistory":["1.1925 -"],"title":[{"subtitle":"AHJ","title":"American heart journal","title_sort":"American heart journal"}],"physDesc":[{"extent":"Online-Ressource"}],"id":{"eki":["313061718"],"zdb":["2003210-9"],"issn":["1097-6744"]},"origin":[{"dateIssuedDisp":"1925-","dateIssuedKey":"1925","publisher":"Elsevier ; Mosby","publisherPlace":"Amsterdam [u.a.] ; St. Louis, Mo."}]}],"physDesc":[{"extent":"7 S."}],"id":{"doi":["10.1016/s0002-8703(99)70155-9"],"eki":["1755917317"]},"origin":[{"dateIssuedKey":"1999","dateIssuedDisp":"1999"}],"name":{"displayForm":["M. Spiecker, J. Windeler, F. Vermeer, R. Michels, R. Seabra-Gomes, J. vom Dahl, S. Kerber, F.W. Verheugt, P.W. Westerhof, F.W. Bär, U. Nixdorff, H. Barth, G.R. Hopkins, M.J. von Fisenne, J. Meyer"]},"language":["eng"],"recId":"1755917317","note":["Elektronische Reproduktion der Druck-Ausgabe","Gesehen am 26.04.2021"],"type":{"bibl":"article-journal","media":"Online-Ressource"},"title":[{"title":"Thrombolysis with saruplase versus streptokinase in acute myocardial infarction","subtitle":"five-year results of the PRIMI trial","title_sort":"Thrombolysis with saruplase versus streptokinase in acute myocardial infarction"}],"person":[{"given":"Martin","family":"Spiecker","role":"aut","roleDisplay":"VerfasserIn","display":"Spiecker, Martin"},{"roleDisplay":"VerfasserIn","display":"Windeler, Jürgen","role":"aut","family":"Windeler","given":"Jürgen"},{"roleDisplay":"VerfasserIn","display":"Vermeer, F.","role":"aut","family":"Vermeer","given":"F."},{"roleDisplay":"VerfasserIn","display":"Michels, R.","role":"aut","family":"Michels","given":"R."},{"role":"aut","roleDisplay":"VerfasserIn","display":"Seabra-Gomes, R.","given":"R.","family":"Seabra-Gomes"},{"family":"vom Dahl","given":"J.","display":"vom Dahl, J.","roleDisplay":"VerfasserIn","role":"aut"},{"role":"aut","roleDisplay":"VerfasserIn","display":"Kerber, S.","given":"S.","family":"Kerber"},{"roleDisplay":"VerfasserIn","display":"Verheugt, F. W.","role":"aut","family":"Verheugt","given":"F. W."},{"display":"Westerhof, P. W.","roleDisplay":"VerfasserIn","role":"aut","family":"Westerhof","given":"P. W."},{"role":"aut","display":"Bär, F. W.","roleDisplay":"VerfasserIn","given":"F. W.","family":"Bär"},{"given":"U.","family":"Nixdorff","role":"aut","display":"Nixdorff, U.","roleDisplay":"VerfasserIn"},{"given":"H.","family":"Barth","role":"aut","roleDisplay":"VerfasserIn","display":"Barth, H."},{"given":"G. R.","family":"Hopkins","role":"aut","display":"Hopkins, G. R.","roleDisplay":"VerfasserIn"},{"display":"von Fisenne, M. J.","roleDisplay":"VerfasserIn","role":"aut","family":"von Fisenne","given":"M. J."},{"given":"J.","family":"Meyer","role":"aut","display":"Meyer, J.","roleDisplay":"VerfasserIn"}]} | ||
| SRT | |a SPIECKERMATHROMBOLYS1999 | ||